Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Marker Therapeutics

Marker Therapeutics

Marker Therapeutics is a biotechnology company developing immunotherapies for the treatment of cancer.

Marker Therapeutics is a company that provides clinical-stage immuno-oncology immunotherapies. The company was founded in 2018, in Houston, Texas, United States.

The company offers T-cell based treatment options for hematological malignancies and solid tumor indications. Their cell therapy technology is based on the selective expansion of non-engineered, and tumor specific T-cells that target specific antigens related to a tumor and kill those related tumor cells. When introduced into the patient, the T-cells attack multiple targets in order to activate an immune system response and produce a broad spectrum of anti-tumor activities.

Marker Therapeutics looks to eventually create treatments for the purpose of fighting lymphoma, multiple myeloma, solid tumors, acute myeloid leukemia, as well as acute lymphoblastic leukemia. They are also pursuing post-transplant treatments against acute myeloid leukemia with their MultiTAA program.

Their MultiTAA therapy is in Phase 2 of clinical trials and is being evaluated for the treatment of breast cancer, lymphoma, multiple myeloma, pancreatic cancer, and sarcoma.

Timeline

2015
Marker Therapeutics was founded.

Patents

Further Resources

Title
Author
Link
Type
Date

Cancer-focused Marker Therapeutics shares rise after update on clinical trial pipeline

Proactive Investors

Web

Marker Therapeutics: Next Major Leap in T-Cell Based Immunotherapies for Cancer

March 11, 2019

TapImmune And Marker Therapeutics Announce Successful Closing Of Previously Announced Merger And Financing

TapImmune

Web

News

Title
Author
Date
Publisher
Description
Marker Therapeutics, Inc.
June 16, 2021
www.prnewswire.com:443
/PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T...
Marker Therapeutics, Inc.
May 12, 2021
www.prnewswire.com:443
/PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T...
Marker Therapeutics, Inc.
April 29, 2021
www.prnewswire.com:443
/PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T...
Marker Therapeutics, Inc.
April 27, 2021
www.prnewswire.com:443
/PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T...
Marker Therapeutics, Inc.
March 9, 2021
www.prnewswire.com:443
/PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T...
SHOW MORE

References

Golden logo
By using this site, you agree to our Terms & Conditions.